Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

News Release

Printer Friendly Version View printer-friendly version
Charles River Laboratories and CHDI Foundation Extend Huntington’s Disease Collaboration

Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work.

WILMINGTON, Mass.--(BUSINESS WIRE)--Apr. 9, 2019-- Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration. The organizations began working together in 2005 on drug discovery and development for Huntington’s disease (HD), a genetic neurological disease that causes the progressive dysfunction of nerve cells in the brain. The extension will allow more flexible activity across the different Charles River platforms and entail greater integration into CHDI’s programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190409005223/en/

The contract extension covers multidisciplinary services from across Charles River’s portfolio, including:

  • Integrated biology and chemistry capabilities
  • Complex primary neuronal assay development
  • High-content and fragment-based screening
  • Computational chemistry
  • Absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetics (PK)
  • Protein crystallography
  • Extensive in vivo pharmacology approaches in research models for translational assessment

Longstanding Collaboration

Over their 14-year collaboration, Charles River has established and validated tools and methodologies within expert teams to support CHDI’s mission of developing novel therapeutics that will substantially improve the lives of those affected by HD.

Together, Charles River and CHDI have identified novel potential drug targets, bred and validated translational research animal models, run large screens and generated proof-of-concept molecules, and evaluated the potential efficacy of both small molecule and biologic candidates in preclinical models of HD. These cutting-edge approaches have resulted in over one hundred co-authored posters and dozens of peer-reviewed papers. Additionally, the expertise developed throughout this partnership has helped more broadly facilitate increased HD research within the larger drug discovery and development community.

Approved Quotes

  • “Our longstanding partnership with CHDI is built on our mutual commitment to developing novel therapies for Huntington’s disease. As an organization, our work with CHDI has led to a much larger commitment to support the HD research community, through investments in methodologies, tools and personnel dedicated to this rare disease.” – Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River
  • “Charles River’s early drug discovery team has continuously delivered scientific expertise that enables our drug discovery research to produce more efficient results. We are excited to continue our research and work toward delivering a meaningful treatment to patients.” –Robi Blumenstein, President, CHDI Management, Inc.
  • “We are continuously inspired by CHDI’s open approach to sharing knowledge and transferring expertise. Our researchers take their work very personally—they are acutely aware of its potential impact—and focus on honing their skills and learning new techniques to help progress HD research forward.” –Outi Kontkanen, Senior Director of Alliance Management at Charles River

About CHDI Foundation, Inc.

CHDI Foundation, Inc. is a privately-funded nonprofit biomedical research organization that is exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease. As a collaborative enabler CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 700 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus. More information about CHDI can be found at www.chdifoundation.org.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Source: Charles River Laboratories International, Inc.

Investor Contact:
Charles River
Todd Spencer
Corporate Vice President, Investor Relations
781-222-6455
todd.spencer@crl.com

Media Contacts:
Charles River
Amy Cianciaruso
Corporate Vice President, Public Relations
781-222-6168
amy.cianciaruso@crl.com

Stock Quote

CRL (common)
Price
$129.41
Change (%)
- 2.56 (1.94%)
Volume
285,623
Exchange
NYSE
Data as of 06/14/19 4:02 p.m. ET
Data provided by Nasdaq.
Minimum 15 minutes delayed.

Refresh Quote

Investor Hotline

877-567-6CRL (6275)